# Mesenchymal Stem Cells for Frailty Syndrome

> **NCT06501066** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Meribank Biotech Co., Ltd.** · enrollment: 66 (actual)

## Conditions studied

- Pathologic Processes

## Interventions

- **BIOLOGICAL:** umbilical cord mesenchymal stem cells

## Key facts

- **NCT ID:** NCT06501066
- **Lead sponsor:** Meribank Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-03
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2024-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06501066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06501066, "Mesenchymal Stem Cells for Frailty Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06501066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*